We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
17
3 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Active, not recruiting
1
5.9%
Not yet recruiting
2
11.8%
Recruiting
9
52.9%
Terminated
4
23.5%
Withdrawn
No approval data available
- SBP Group's subsidiary Chia Tai Tianqing Pharmaceutical has received NDA acceptance from China's CDE for M701, a CD3/EpCAM bispecific antibody targeting malignant ascites. - M701 represents China's first independently developed CD3/EpCAM bispecific antibody, designed to simultaneously target EpCAM on tumor cells and CD3 on immune T cells. - The innovative drug activates T cells to kill tumor cells by forming a bridge between tumor cells and immune T cells through dual-target binding. - This milestone follows several other regulatory achievements for SBP Group, including approvals for naldemedine, culmerciclib, and clinical trial authorization for TQB3205.
